<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.0//EN" "http://www.ncbi.nlm.nih.gov:80/entrez/query/static/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>Iranian Pediatric Hematology and Oncology Society</PublisherName>
<JournalTitle>Iranian Journal of Blood and Cancer</JournalTitle>
<Issn>2008-4595</Issn>
<Volume>5</Volume>
<Issue>2</Issue>
<PubDate PubStatus = "ppublish">
<Year>2013</Year>
<Month>1</Month>
<Day>1</Day>
</PubDate>
</Journal>


	<ArticleTitle>Table of contents</ArticleTitle>
	<FirstPage>0</FirstPage>
	<LastPage>0</LastPage>
	<Language>EN</Language>
<AuthorList>
</AuthorList>
<Abstract></Abstract>


</Article>
<Article>
<Journal>
<PublisherName>Iranian Pediatric Hematology and Oncology Society</PublisherName>
<JournalTitle>Iranian Journal of Blood and Cancer</JournalTitle>
<Issn>2008-4595</Issn>
<Volume>5</Volume>
<Issue>2</Issue>
<PubDate PubStatus = "ppublish">
<Year>2013</Year>
<Month>1</Month>
<Day>1</Day>
</PubDate>
</Journal>


	<ArticleTitle>Members Information Pack</ArticleTitle>
	<FirstPage>0</FirstPage>
	<LastPage>0</LastPage>
	<Language>EN</Language>
<AuthorList>
</AuthorList>
<Abstract></Abstract>


</Article>
<Article>
<Journal>
<PublisherName>Iranian Pediatric Hematology and Oncology Society</PublisherName>
<JournalTitle>Iranian Journal of Blood and Cancer</JournalTitle>
<Issn>2008-4595</Issn>
<Volume>5</Volume>
<Issue>2</Issue>
<PubDate PubStatus = "ppublish">
<Year>2013</Year>
<Month>1</Month>
<Day>1</Day>
</PubDate>
</Journal>


	<ArticleTitle>The Prevalence and Risk Factors for Neonatal Thrombocytopenia among Newborns Admitted to Intensive Care Unit of Aliasghar Children’s Hospital</ArticleTitle>
	<FirstPage>41</FirstPage>
	<LastPage>45</LastPage>
	<Language>EN</Language>
<AuthorList>
	<Author>
	<FirstName>Sara</FirstName>
	<LastName>Sanii</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Nasrin</FirstName>
	<LastName>Khalessi</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Nastaran</FirstName>
	<LastName>Khosravi</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Fatemeh</FirstName>
	<LastName>Zareh Mehrjerdi</LastName>
	<Affiliation></Affiliation>
	 </Author>


</AuthorList>
<Abstract>Background: Determining the prevalence and risk factors of thrombocytopenia among neonates enables us to
prevent the inevitable and sometimes irreversible complications. In this study we aimed to survey the frequency of
thrombocytopenia and its demographic features and risk factors.
Materials and methods: In this cross sectional study the platelet counts of 364 neonates admitted to neonatal
intensive care unit of Aliasghar children’s hospital, Tehran, Iran, were assessed. Maternal and neonatal medical
conditions, risk factors and drug history were also recorded. Patients were divided into 4 groups according to the
severity of thrombocytopenia: mild (100-149 × 109/L), moderate (50-99 × 109/L), severe (30-49 × 109/L) and very
severe (&#60; 30 × 109/L).They were also grouped as presenting early (less than 72 hours after birth) and late (more than
72 hours after birth) thrombocytopenia. Demographic data and hemorrhagic manifestations were also recorded.
Results: Sixty two (17.9%) of neonates were thrombocytopenic. The average gestational age at birth for the
thrombocytopenic neonates was significantly lower than the non thrombocytopenic neonates (32.2 ±2.5 weeks
versus 34.9± 2.5, P=0.0001), and also the average birth weight was significantly lower among the thrombocytopenic
neonates (1979±517gr versus 2371±480 gr, P=0.0001). Neonatal sepsis was significantly associated with
thrombocytopenia (24.1% versus 5.9%, P=0.0001).
Conclusion: Our study indicated a high prevalence of thrombocytopenia among neonates admitted to NICU and its
association with low birth weight, prematurity, and neonatal sepsis. Regarding the importance of life threatening
events among the thrombocytopenic newborns, it is best to keep the risk factors in mind to prevent the future
complications.
Key words: Thrombocytopenia, risk factor, neonate, preterm</Abstract>


</Article>
<Article>
<Journal>
<PublisherName>Iranian Pediatric Hematology and Oncology Society</PublisherName>
<JournalTitle>Iranian Journal of Blood and Cancer</JournalTitle>
<Issn>2008-4595</Issn>
<Volume>5</Volume>
<Issue>2</Issue>
<PubDate PubStatus = "ppublish">
<Year>2013</Year>
<Month>1</Month>
<Day>1</Day>
</PubDate>
</Journal>


	<ArticleTitle>Metronomic Capecitabine for Elderly Advanced Gastric Carcinoma Patients Pretreated With One or Two Systemic Chemotherapy Lines</ArticleTitle>
	<FirstPage>47</FirstPage>
	<LastPage>55</LastPage>
	<Language>EN</Language>
<AuthorList>
	<Author>
	<FirstName>Amal</FirstName>
	<LastName>Halim</LastName>
	<Affiliation></Affiliation>
	 </Author>


</AuthorList>
<Abstract>Background: The aim of this study was to investigate the efficacy and safety of metronomic capecitabine chemotherapy
in pretreated elderly patients with advanced gastric carsonoma.
Patients and Methods: Eligible patients were treated with capecitabine at a fixed dose of 1000mg daily until disease
progression or toxicity. Endpoints were overall response rate, safety, progression-free survival and overall survival.
Results: Thirty eight patients were enrolled (June 2004 to October 2011) with a median age of 69 years. Two patients
refused continuation due to deterioration of general condition consequently, 36 out of 38 patients were assessed
for response. No complete response was observed while 6 patients out of 36 patients (16.7%) achieved partial
response, 13 (36.1%) showed stable disease and 17 (47.2%) showed progression of disease. The disease control rate
(response rate + stability rate) was 52.8%. The most common hematologic adverse effects were neutropenia in 3
(8.3%), followed by mucositis in 2 (5.6%) patients. There was one reported case of neutropenic fever. The reported
hand-foot syndrome cases were all lower than grade 3. There were no treatment-related deaths and treatment
delays were observed in 8 patients. Symptomatic improvement was evident in 18 patients (50 %). Median follow-up
period was 6.5 months. Median time to progression was 3 months (range: 0 to7 months), while the median overall
survival was 7 months (range: 3 to15 months).
Conclusion: Metronomic capecitabine may be considered an effective and tolerable treatment option in elderly
patients with pretreated advanced gastric cancer after the failure of previous lines of chemotherapy.
Key words: Metronomic, capecitabine, gastric, cancer, elderly.</Abstract>


</Article>
<Article>
<Journal>
<PublisherName>Iranian Pediatric Hematology and Oncology Society</PublisherName>
<JournalTitle>Iranian Journal of Blood and Cancer</JournalTitle>
<Issn>2008-4595</Issn>
<Volume>5</Volume>
<Issue>2</Issue>
<PubDate PubStatus = "ppublish">
<Year>2013</Year>
<Month>1</Month>
<Day>1</Day>
</PubDate>
</Journal>


	<ArticleTitle>The effect of on demand and prophylactic therapeutic methods on quality of life among hemophilic children</ArticleTitle>
	<FirstPage>57</FirstPage>
	<LastPage>60</LastPage>
	<Language>EN</Language>
<AuthorList>
	<Author>
	<FirstName>Eshghi</FirstName>
	<LastName>P</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Khanali</FirstName>
	<LastName>L</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Abed-Saeedi</FirstName>
	<LastName>J</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Farahani</FirstName>
	<LastName>H</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Abdolah Gorgi</FirstName>
	<LastName>F</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Habib- Panah</FirstName>
	<LastName>B</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Tehrani Tarighat</FirstName>
	<LastName>S</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Alavi</FirstName>
	<LastName>S</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Taslimi</FirstName>
	<LastName>S</LastName>
	<Affiliation></Affiliation>
	 </Author>


</AuthorList>
<Abstract>Background: Treating a chronic disease such as hemophilia is to improve the symptoms and quality of life (QOL) of
the patients. This study aimed to study the quality of life among hemophilic children and compare the quality of life
between patients receiving prophylactic or on demand treatments.
Materials and Methods: In this descriptive-comparative study, we enrolled 60 patients from three main hemophilia
care centers in Tehran. All patients were 4-7 year old. Half of the patients were receiving prophylactic and half were
receiving on-demand treatment. The assessment tool was Heamo-QoL questionnaire which assesses the quality
of life in different dimensions (physical, feeling, family, friends, others, attitude, treatment and behavior). In this
instrument, higher points correspond to lower quality of life. The mean quality of life in each dimension and also the
total score were determined. Quality of life was compared between prophylactic and on demand treatments.
Results: The mean quality of life in groups receiving prophylactic and on-demand treatments were 2.6±0.3 and
3.33±0.4 respectively (P&#60;0.001). All dimensions except “treatment” and “feeling” were different between groups. The
highest impairments among patients, regardless of their treatment regimen, were in family and physical dimensions.
Conclusion: It is necessary to pay more attention to prophylactic treatment in hemophilic children as it seems to
provide a higher quality of life among patients.
Keywords: Hemophilia, quality of life, prophylactic, treatment, on demand, Heamo-QoL.</Abstract>


</Article>
<Article>
<Journal>
<PublisherName>Iranian Pediatric Hematology and Oncology Society</PublisherName>
<JournalTitle>Iranian Journal of Blood and Cancer</JournalTitle>
<Issn>2008-4595</Issn>
<Volume>5</Volume>
<Issue>2</Issue>
<PubDate PubStatus = "ppublish">
<Year>2013</Year>
<Month>1</Month>
<Day>1</Day>
</PubDate>
</Journal>


	<ArticleTitle>Occult Hepatitis B Infection and Its Role in Blood Safety: a Review</ArticleTitle>
	<FirstPage>61</FirstPage>
	<LastPage>75</LastPage>
	<Language>EN</Language>
<AuthorList>
	<Author>
	<FirstName>Amir Mohammad</FirstName>
	<LastName>Alborzi</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Omid</FirstName>
	<LastName>Kiani Ghalesardi</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Taravat</FirstName>
	<LastName>Bamdad</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Ali Akbar</FirstName>
	<LastName>Pourfathollah</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Mohammad Ali</FirstName>
	<LastName>Jalalifar</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Mohammad</FirstName>
	<LastName>Shahjahani</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Mohammad</FirstName>
	<LastName>Kazemi Arababadi</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Ali</FirstName>
	<LastName>Dehghani Fard</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Najmaldin</FirstName>
	<LastName>Saki</LastName>
	<Affiliation></Affiliation>
	 </Author>


</AuthorList>
<Abstract>Background: Blood transfusion plays a great role in public health and the blood safety still has remained a main
concern. HBV has been considered as one of the most prevalent blood borne infections. It is estimated that chronic
HBV affects 350-400 million people worldwide. Comprehensive knowledge about HBV has high importance in Iran
due to high number of blood dependent patients.
Material and methods: The data used in this research are derived from articles obtained by searching keywords like
occult hepatitis B infection, thalassemia, hemophilia, hemodialysis, co-infection and blood transfusion in databases
including PubMed, Google Scholar and Scopus. The prevalence, genotypes, HBV-HCV co-infection, HIV-HBV coinfection
and their role in blood transfusion and blood safety are discussed in this review article.
Results: Iran is in intermediate endemicity region and studies have reported that between 10–60% of the Iranian
population has the evidence of HBV infection, with 2-7% being chronic carriers. In blood donors the rate of infection
is lower than general population. The occult hepatitis B infection is the main concern in blood safety due to
transmission of the HBV via seronegative blood components. Iranian researches have reported a 1-2% prevalence of
occult hepatitis B infection among Iranian blood donors.
Conclusion: Based on our review findings the prevalence of HBV and occult hepatitis B infection in Iran is moderate,
which shows the importance of taking necessary steps to reduce the transfer of infection via blood and its components.
Keywords: Hepatitis B virus, prevalence, blood donor, safety.</Abstract>


</Article>
<Article>
<Journal>
<PublisherName>Iranian Pediatric Hematology and Oncology Society</PublisherName>
<JournalTitle>Iranian Journal of Blood and Cancer</JournalTitle>
<Issn>2008-4595</Issn>
<Volume>5</Volume>
<Issue>2</Issue>
<PubDate PubStatus = "ppublish">
<Year>2013</Year>
<Month>1</Month>
<Day>1</Day>
</PubDate>
</Journal>


	<ArticleTitle>Eye Lymphoma: a Case Report</ArticleTitle>
	<FirstPage>77</FirstPage>
	<LastPage>81</LastPage>
	<Language>EN</Language>
<AuthorList>
	<Author>
	<FirstName>Abdessamad</FirstName>
	<LastName>Arabi</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Abdelbaki</FirstName>
	<LastName>Boukerche</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Mohamed</FirstName>
	<LastName>Bey</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Samira</FirstName>
	<LastName>Bouchama</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Lila</FirstName>
	<LastName>Charef</LastName>
	<Affiliation></Affiliation>
	 </Author>


	<Author>
	<FirstName>Mohamed-Amine</FirstName>
	<LastName>Bekadja</LastName>
	<Affiliation></Affiliation>
	 </Author>


</AuthorList>
<Abstract>Non Hodgkin Lymphomas (NHL) are nodal or extra nodal monoclonal infiltrations by malignant lymphoid cells (B
Lymphocytes in 80% of cases), which are distinguished as indolent or aggressive forms.
According to the heterogeneity of lymphoid cells and their ubiquitous anatomical distribution, these disorders can
develop in any organ and have very heterogeneous clinical expressions, but they are usually expressed by tumor
development in the lymphoid tissue (lymph nodes, Waldeyer ring, spleen, bone marrow and sometimes blood).
We report a patient referred to the department of hematology and bone marrow transplantation with an unusual
localization for this type of pathology: eye localized phenotype B lymphoma in its aggressive form, occurring in a 88
years old man.
Clinical remission was obtained by using rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone
protocol combined with radiotherapy.
Keywords: Non Hodgkin lymphoma, aggressive, eye, remission.</Abstract>


</Article>
</ArticleSet>
